Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-292.5%
operating margin TTM
-319.32%
revenue TTM
113.26 Million
revenue per share TTM
1.47$
valuation ratios | |
|---|---|
| pe ratio | -6.64 |
| peg ratio | 0.48 |
| price to book ratio | 4.36 |
| price to sales ratio | 17.73 |
| enterprise value multiple | -5.99 |
| price fair value | 4.36 |
profitability ratios | |
|---|---|
| gross profit margin | -162.86% |
| operating profit margin | -319.32% |
| pretax profit margin | -291.58% |
| net profit margin | -292.5% |
| return on assets | -46.85% |
| return on equity | -53.57% |
| return on capital employed | -60.72% |
liquidity ratios | |
|---|---|
| current ratio | 5.35 |
| quick ratio | 5.35 |
| cash ratio | 0.95 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 0.00 |
| operating cycle | 7.41 |
| days of payables outstanding | 14.28 |
| cash conversion cycle | -6.87 |
| receivables turnover | 49.23 |
| payables turnover | 25.55 |
| inventory turnover | 0.00 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.11 |
| debt equity ratio | 0.15 |
| long term debt to capitalization | 0.00 |
| total debt to capitalization | 0.13 |
| interest coverage | 0.00 |
| cash flow to debt ratio | -4.08 |
cash flow ratios | |
|---|---|
| free cash flow per share | -2.87 |
| cash per share | 5.10 |
| operating cash flow per share | -2.74 |
| free cash flow operating cash flow ratio | 1.05 |
| cash flow coverage ratios | -4.08 |
| short term coverage ratios | -60.77 |
| capital expenditure coverage ratio | -20.99 |
Frequently Asked Questions
When was the last time Nurix Therapeutics, Inc. (NASDAQ:NRIX) reported earnings?
Nurix Therapeutics, Inc. (NRIX) published its most recent earnings results on 09-10-2025.
What is Nurix Therapeutics, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Nurix Therapeutics, Inc. (NASDAQ:NRIX)'s trailing twelve months ROE is -53.57%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Nurix Therapeutics, Inc. (NRIX) currently has a ROA of -46.85%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did NRIX's net profit margin stand at?
NRIX reported a profit margin of -292.5% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is NRIX's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 5.35 in the most recent quarter. The quick ratio stood at 5.35, with a Debt/Eq ratio of 0.15.